Document is current
Any future updates will be listed below
-
Authors
Periman, Laura M.
White, Darrell E.
Katsev, Douglas
-
Funding
Funding for this research was provided by:
Bausch + Lomb (Funding for editorial assistance)
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 20 November 2024
First Online: 7 January 2025
Declarations
:
: Laura M. Periman reports serving on advisory boards, speakers bureaus, and/or as a consultant for Alcon, Aldeyra Therapeutics, Allergan, Amgen, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Dompé, Eyedetec Medical, Kala Pharmaceuticals, Lumenis Be, Mallinckrodt, Myze, Novartis Pharmaceuticals, Nusight Medical, Olympic Ophthalmics, Science Based Health, Scope Health, Sun Pharmaceutical Industries, Tarsus, ThermaMEDx, Verséa, Visant, and Viatris; serving as a principal investigator for Alcon, Bausch + Lomb, Kala Pharmaceuticals, Lumenis Be, Novartis Pharmaceuticals, Olympic Ophthalmics, Tarsus, and Viatris; and is a shareholder of Eyedetec Medical, Myze, Quench Method, ThermaMEDx, Verséa, and Visant. Darrell E. White reports serving as a consultant and speaker to Bausch + Lomb. Douglas Katsev reports serving as a consultant and speaker to Bausch + Lomb. Douglas Katsev has no financial interest in the subject matter of this manuscript. The authors report no other conflicts of interest in this work.
: This article is based on previously conducted studies and does not contain any new studies performed by any of the authors on human participants or animals.
